Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MTR-601, a Novel Oral Treatment in Patients With Cervical Dystonia

NCT06830642 is registered in ClinicalTrials.gov with Motric Bio as lead sponsor.

NCT NCT06830642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MTR-601, a Novel Oral Treatment in Patients With Cervical Dystonia
Lead sponsor
Motric Bio
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2025
Completion date
December 18, 2025
Enrollment
38 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cervical dystonia